Lipid-lowering therapy has been shown to reduce cardiovascular events in a variety of studies.

Atherosclerosis is often advanced before symptoms appear, and it is not clear whether the treatment advantageous middle-aged used with a low Framingham risk score will moderate and mild to subclinical atherosclerosis.. Lipid-lowering therapy has been shown to reduce cardiovascular events in a variety of studies. Statins and other agents and lifestyle changes have also been shown to slow down the progression of atherosclerosis that and even regress, according to background information in the article.

Dose of rosuvastatin on carotid intima-media thickness over two years in middle age with low Framingham risk scores, but with evidence of subclinical atherosclerosis. [ Bad cholesterol] level, a 34 % reduction in total cholesterol, eight % increase in HDL – C[ good cholesterol] level rosuvastatin with a 49 – % reduction in LDL-C was associated a 16 a 16 % reduction in the levels of triglycerides, the authors write. – Compared with placebo, rosuvastatin significantly slowed the progression of maximum CIMT for the 12 carotid sites, they continues, S.lthough the study does not prove, has regression of disease with rosuvastatin.An additional two-person team to Colombo to Colombo. An will come tonight, the different day after tomorrow. Left A third team from Switzerland – .

In Australia, ten volunteers at stand-by to leave as soon as need for short-term emissions.

Thailand:MSF is have explorative team of on their way in Phuket day. Team gathering information, two-person non-food relief item like blankets and plastic sheets from local markets for immediate distribution.